Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18

Arnulf Stenzl; Nigel C. Cowan; Maria De Santis; Markus A. Kuczyk; Axel S. Merseburger; Maria José Ribal; Amir Sherif; J. Alfred Witjes; Thierry Lebret

doi:10.1016/j.eururo.2012.04.042

Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18

Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, Markus A. Kuczyk, Axel S. Merseburger, Maria José Ribal, Amir Sherif, J. Alfred Witjes, Thierry Lebret

Clinic of Urology

3 Citations (Scopus)

Original language	English
Journal	European Urology
Volume	62
Issue number	2
Pages (from-to)	45-46
Number of pages	2
ISSN	0302-2838
DOIs	https://doi.org/10.1016/j.eururo.2012.04.042
Publication status	Published - 08.2012

Funding

Dr. Stenzl is a company consultant for GE Healthcare and Novartis; has received speaker honoraria from Amgen and Novartis; has participated in trials for MEDAC, Photocure, Immatics, Novartis, Johnson & Johnson, Amgen, and Bayer; and has received research grants from Immatics. Dr. Witjes is a company consultant for Endo Pharm, Astellas, Spectrum Pharmaceuticals, Sanofi Pasteur, GE Healthcare, and Telormedix; has received speaker honoraria from GE Healthcare; and has participated in trials for MEL Amsterdam, Telormedix, and Photocure Oslo. Dr. Cowan has nothing to disclose. Dr. de Santis is a company consultant for Glaxo Smith Kline, Amgen, Bayer, Novartis, and Pierre-Fabre; has received speaker honoraria from Pfizer, Eli Lilly, Sanofi Aventis, Novartis, and Roche; has received fellowship and travel grants from Bayer, Novartis, Pfizer, Amgen, and Sanofi Aventis. Dr. Kuczyk has equity interests in Bayer Healtcare, Astellas, Storz, Pfizer, and Wyeth; is a company consultant for Bayer Healthcare, Pfizer, Astra Zeneca, Astellas, and Storz; has received speaker honoraria from Bayer, Pfizer, Medac, Astellas, Bayer Healthcare, and Astellas; has participated in trials for Astra Zeneca, Pfizer, Bayer Healthcare, Astellas, and Ipsen; and has received research grants from Wyeth. Dr. Merseburger is a company consultant for Ipsen Pharma and Bayer; has received speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, and SEP; has participated in trials for Astra Zeneca, Bayer, Pfizer, TEVA, and Novartis; and has received research grants from Wyeth. Dr. Sherif has received speaker honoraria from Orion Pharma and MEDAC AB. Dr. Lebret is a company consultant for Ipsen, Amgen, Sanofi, and Novartis; has received speaker honoraria from Ferring; and has participated in trials for Astellas and Takeda.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

Access to Document

10.1016/j.eururo.2012.04.042

Cite this

Stenzl, A., Cowan, N. C., De Santis, M., Kuczyk, M. A., Merseburger, A. S., Ribal, M. J., Sherif, A., Witjes, J. A., & Lebret, T. (2012). Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18. European Urology, 62(2), 45-46. https://doi.org/10.1016/j.eururo.2012.04.042

@article{25c031e037a34800b4595d86c270b2e8,

title = "Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18",

author = "Arnulf Stenzl and Cowan, \{Nigel C.\} and \{De Santis\}, Maria and Kuczyk, \{Markus A.\} and Merseburger, \{Axel S.\} and Ribal, \{Maria Jos{\'e}\} and Amir Sherif and Witjes, \{J. Alfred\} and Thierry Lebret",

note = "Funding Information: Dr. Stenzl is a company consultant for GE Healthcare and Novartis; has received speaker honoraria from Amgen and Novartis; has participated in trials for MEDAC, Photocure, Immatics, Novartis, Johnson \& Johnson, Amgen, and Bayer; and has received research grants from Immatics. Dr. Witjes is a company consultant for Endo Pharm, Astellas, Spectrum Pharmaceuticals, Sanofi Pasteur, GE Healthcare, and Telormedix; has received speaker honoraria from GE Healthcare; and has participated in trials for MEL Amsterdam, Telormedix, and Photocure Oslo. Dr. Cowan has nothing to disclose. Dr. de Santis is a company consultant for Glaxo Smith Kline, Amgen, Bayer, Novartis, and Pierre-Fabre; has received speaker honoraria from Pfizer, Eli Lilly, Sanofi Aventis, Novartis, and Roche; has received fellowship and travel grants from Bayer, Novartis, Pfizer, Amgen, and Sanofi Aventis. Dr. Kuczyk has equity interests in Bayer Healtcare, Astellas, Storz, Pfizer, and Wyeth; is a company consultant for Bayer Healthcare, Pfizer, Astra Zeneca, Astellas, and Storz; has received speaker honoraria from Bayer, Pfizer, Medac, Astellas, Bayer Healthcare, and Astellas; has participated in trials for Astra Zeneca, Pfizer, Bayer Healthcare, Astellas, and Ipsen; and has received research grants from Wyeth. Dr. Merseburger is a company consultant for Ipsen Pharma and Bayer; has received speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, and SEP; has participated in trials for Astra Zeneca, Bayer, Pfizer, TEVA, and Novartis; and has received research grants from Wyeth. Dr. Sherif has received speaker honoraria from Orion Pharma and MEDAC AB. Dr. Lebret is a company consultant for Ipsen, Amgen, Sanofi, and Novartis; has received speaker honoraria from Ferring; and has participated in trials for Astellas and Takeda. Copyright: Copyright 2013 Elsevier B.V., All rights reserved.",

year = "2012",

month = aug,

doi = "10.1016/j.eururo.2012.04.042",

language = "English",

volume = "62",

pages = "45--46",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "2",

}

Stenzl, A, Cowan, NC, De Santis, M, Kuczyk, MA, Merseburger, AS, Ribal, MJ, Sherif, A, Witjes, JA & Lebret, T 2012, 'Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18', European Urology, vol. 62, no. 2, pp. 45-46. https://doi.org/10.1016/j.eururo.2012.04.042

Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18. / Stenzl, Arnulf; Cowan, Nigel C.; De Santis, Maria et al.
In: European Urology, Vol. 62, No. 2, 08.2012, p. 45-46.

Research output: Journal Articles › Letters › peer-review

TY - JOUR

T1 - Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18

AU - Stenzl, Arnulf

AU - Cowan, Nigel C.

AU - De Santis, Maria

AU - Kuczyk, Markus A.

AU - Merseburger, Axel S.

AU - Ribal, Maria José

AU - Sherif, Amir

AU - Witjes, J. Alfred

AU - Lebret, Thierry

N1 - Funding Information: Dr. Stenzl is a company consultant for GE Healthcare and Novartis; has received speaker honoraria from Amgen and Novartis; has participated in trials for MEDAC, Photocure, Immatics, Novartis, Johnson & Johnson, Amgen, and Bayer; and has received research grants from Immatics. Dr. Witjes is a company consultant for Endo Pharm, Astellas, Spectrum Pharmaceuticals, Sanofi Pasteur, GE Healthcare, and Telormedix; has received speaker honoraria from GE Healthcare; and has participated in trials for MEL Amsterdam, Telormedix, and Photocure Oslo. Dr. Cowan has nothing to disclose. Dr. de Santis is a company consultant for Glaxo Smith Kline, Amgen, Bayer, Novartis, and Pierre-Fabre; has received speaker honoraria from Pfizer, Eli Lilly, Sanofi Aventis, Novartis, and Roche; has received fellowship and travel grants from Bayer, Novartis, Pfizer, Amgen, and Sanofi Aventis. Dr. Kuczyk has equity interests in Bayer Healtcare, Astellas, Storz, Pfizer, and Wyeth; is a company consultant for Bayer Healthcare, Pfizer, Astra Zeneca, Astellas, and Storz; has received speaker honoraria from Bayer, Pfizer, Medac, Astellas, Bayer Healthcare, and Astellas; has participated in trials for Astra Zeneca, Pfizer, Bayer Healthcare, Astellas, and Ipsen; and has received research grants from Wyeth. Dr. Merseburger is a company consultant for Ipsen Pharma and Bayer; has received speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, and SEP; has participated in trials for Astra Zeneca, Bayer, Pfizer, TEVA, and Novartis; and has received research grants from Wyeth. Dr. Sherif has received speaker honoraria from Orion Pharma and MEDAC AB. Dr. Lebret is a company consultant for Ipsen, Amgen, Sanofi, and Novartis; has received speaker honoraria from Ferring; and has participated in trials for Astellas and Takeda. Copyright: Copyright 2013 Elsevier B.V., All rights reserved.

PY - 2012/8

Y1 - 2012/8

UR - https://www.scopus.com/pages/publications/84862856868

U2 - 10.1016/j.eururo.2012.04.042

DO - 10.1016/j.eururo.2012.04.042

M3 - Letters

C2 - 22579356

AN - SCOPUS:84862856868

SN - 0302-2838

VL - 62

SP - 45

EP - 46

JO - European Urology

JF - European Urology

IS - 2

ER -

Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ et al. Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18. European Urology. 2012 Aug;62(2):45-46. doi: 10.1016/j.eururo.2012.04.042

Reply to Santhanam Sundar's letter to the Editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria de Santis, et al. Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59:1009-18

Funding

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Cite this